Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3526-3538

  Xin, Wenyu ^a,b,c   Huang, Chao ^a   Zhang, Xue ^a   Xin, Sheng ^d   Zhou, Yiming ^e   Ma, Xiaowei ^a   Zhang, Dan ^a   Li, Yongjie ^a   Zhou, Sibai ^a   Zhang, Dongming ^a   Zhang, Tiantai ^a,b   Du, Guanhua ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b YANTAI UNIVERSITY   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CIA; cyclooxygenase; fibroblast like synoviocytes; methyl salicylate 2 O d lactoside; NF B signal pathway; pro inflammatory cytokine; rheumatoid arthritis

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; METHYLSALICYLATE LACTOSIDE; NATURAL PRODUCT; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; AUTACOID; COLLAGEN; LACTOSE; METHYL SALICYLATE 2-O-LACTOSIDE; SALICYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STOMACH MUCOSA; SYNOVIOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; ANKLE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; CHEMICALLY INDUCED; CHEMISTRY; DBA MOUSE; DRUG EFFECTS; INFLAMMATION; METABOLISM; PATHOLOGY; SYNOVIUM; WISTAR RAT;

ANIMALS; ANKLE JOINT; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; COLLAGEN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LACTOSE; MALE; MICE; MICE, INBRED DBA; RATS; RATS, WISTAR; SALICYLATES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903132637     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12715     Document Type: Article

References (36)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV, (2005). NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115: 1848-1854.
3. Baigent C, Patrono C, (2003). Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. Arthritis Rheum 48: 12-20.
4. Bertelsen M, (2006). Multiplex analysis of inflammatory signaling pathways using a high-content imaging system. Methods Enzymol 414: 348-363.
5. Brooks J, Warburton R, lan Beales LP, (2013). Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis 4: 206-222.
6. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. (2002). Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 614-624.
7. Feldmann M, Maini RN, (2001). Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
8. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M, (2009). Caspase 1-independent activation of interleukin-1β in neutrophil- predominant inflammation. Arthritis Rheum 60: 3642-3650.
9. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T, (2006). Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 45: 669-675.
10. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB, (1999). IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 163: 5049-5055.
11. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. (2004). Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400-1411.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
13. Lee YR, Hwang JK, Lee SH, Cheon YJ, Ryu JH, Lee SI, et al. (2011). SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis. Br J Pharmacol 164: 794-806.
14. Liu R, Wu CX, Zhou D, Yang F, Tian S, Zhang L, et al. (2012). Pinocembrin protects against beta-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC Med 10: 105.
15. Ma XJ, Zheng JH, Chen XZ, (2001). Studies on resources of ethnomedicine Gaultheria leucocarpa var. yunnanensis. Zhongguo Zhong Yao Za Zhi 26: 85-89.
16. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
17. McInnes IB, Schett G, (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442.
18. di Meglio P, Ianaro A, Ghosh S, (2005). Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 52: 951-958.
19. Mor A, Abramson SB, Pillinger MH, (2005). The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115: 118-128.
20. Moreland LW, (1998). Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 24: 579-591.
21. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S, (2005). Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 102-110.
22. Okamoto T, (2006). NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 6: 359-372.
23. Okazaki Y, Sawada T, Nagatani K, Komagata Y, Inoue T, Muto S, et al. (2005). Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J Rheumatol 32: 1440-1447.
24. Perkins ND, (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
25. Russell RI, (2001). Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad Med J 77: 82-88.
26. Simmonds RE, Foxwell BM, (2008). NF-κB and its relative to arthritis and inflammation. Rheumatology 47: 584-590.
27. Smolen JS, Steiner G, (2003). Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2: 473-488.
28. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. (2008). Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997.
29. Tran CN, Lundy SK, Fox DA, (2005). Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 12: 183-189.
30. Wang C, Zhang TT, Du GH, Zhang DM, (2011). Synthesis and anti-nociceptive and anti-inflammatory effects of gaultherin and its analogs. J Asian Nat Prod Res 13: 817-825.
31. Wessels JAM, Huizinga TWJ, Guchelaar HJ, (2008). Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47: 249-255.
32. White WB, (2007). Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 49: 408-418.
33. Xin WY, Huang C, Zhang X, Zhang GD, Ma XW, Sun L, et al. (2013). Evaluation of the new anti-inflammatory compound ethyl salicylate 2-O-β-D-glucoside and its possible mechanism of action. Int Immunopharmacol 15: 303-308.
34. Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, et al. (2007). Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 46: 920-926.
35. Yang K, Bai HJ, Ouyang Q, Lai LH, Tang C, (2008). Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 4: 228.
36. Zhang TT, Sun L, Liu R, Zhang D, Lan X, Huang C, et al. (2012). A novel naturally occurring salicylic acid analogue acts as an anti-inflammatory agent by inhibiting nuclear factor-kappaB activity in RAW264.7 macrophages. Mol Pharm 9: 671-677.